Breast Cancer

Videos

Experts provide insights on clinical decision-making in the setting of patient with HER2+ breast cancer.

Decision Making in Selecting Treatment in HER2+ BC

Key opinion leaders explore the appropriateness of prophylactic therapy for brain metastases and  share their thoughts on best practices.

The Role of Prophylactic Therapy in HER2+ BC

An expert panel of breast oncologists discusses factors they consider when deciding whether to screen a patient with HER2+ breast cancer for brain metastases.

Management Approaches for Patients with HER2+ BC at Risk for Brain Metastases

Adam Brufsky, MD, PhD, presents the case of a 37-year-old woman with HER2+/HR- metastatic breast cancer and polls the audience about screening for brain metastases.

Patient Case: A 37-Year-Old Woman With HER2+/HR- Breast Cancer

Articles

Anti-HER2 blockade without chemotherapy in the treatment of HER2-positive early breast cancer may be possible in patients with certain RNA expression signatures. 

Certain RNA Expression Signatures Are Predictive of Outcomes for HER2+ Early Breast Cancer

The KATHERINE trial found a clinical benefit without increasing the risk of CNS recurrence for patients with HER2-positive early breast cancer treated with T-DM1.

Subgroup Analyses of KATHERINE Trial Promote T-DM1 Use in High-Risk Groups

Even though the trastuzumab/radiotherapy failed to meet the trial-specified reduction threshold, a modest, statistically nonsignificant reduction in ipsilateral breast cancer rates were observed.

Trastuzumab Plus Radiotherapy Did Not Achieve Significant Reduction in Ipsilateral Breast Cancer Rates for HER2-Positive DCIS

Experts discusses the treatment of patients with HER2-positive breast cancer in a virtual CancerNetwork® Around the Practice presentation,“Relapsed/Refractory HER2+ Metastatic Breast Cancer,” held January 21, 2021, and moderated by Adam M. Brufsky, MD, PhD.

Around the Practice: Relapsed/Refractory HER2+ Metastatic Breast Cancer

In a retrospective review published in NPJ Breast Cancer, data indicate that omitting radiation therapy results in decreased overall survival in patients with stage I HER2-positive breast cancer.

Radiation Therapy Omission Not Advised in Early-Stage HER2+ Breast Cancer

Pyrotinib plus capecitabine to treat patients with HER2-positive metastatic breast cancer saw a statistically significant improvement in progression-free survival.

HER2-Positive Breast Cancer | Topics